Compare · FBRX vs NVO
FBRX vs NVO
Side-by-side comparison of Forte Biosciences Inc. (FBRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FBRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 570.7x FBRX ($320.9M).
- Over the past year, FBRX is up 34.9% and NVO is down 45.2% - FBRX leads by 80.1 points.
- FBRX has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 12 for FBRX).
- Company
- Forte Biosciences Inc.
- Novo Nordisk A/S
- Price
- $15.73-0.32%
- $41.35+0.84%
- Market cap
- $320.9M
- $183.15B
- 1M return
- -34.38%
- -10.26%
- 1Y return
- +34.91%
- -45.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- News (4w)
- 11
- 8
- Recent ratings
- 12
- 25
Forte Biosciences Inc.
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest FBRX
- SEC Form SCHEDULE 13G filed by Forte Biosciences Inc.
- Amendment: SEC Form S-3/A filed by Forte Biosciences Inc.
- SEC Form 4 filed by Director Doberstein Stephen K
- SEC Form S-3 filed by Forte Biosciences Inc.
- SEC Form 4 filed by Director Kapoor Shivpreet Singh
- SEC Form 4 filed by Director Vincent Richard G
- SEC Form 4 filed by Director Gryska David W
- SEC Form 4 filed by Director Brun Scott C.
- SEC Form 4 filed by Director Kornfeld Steven
- SEC Form S-8 filed by Forte Biosciences Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care